Stockreport

IO Biotech Reports First Quarter 2024 Financial Results and Provides Business Highlights

IO Biotech, Inc.  (IOBT) 
PDF Outcome of interim analysis for the overall response rate (ORR) for the first 225 patients randomized in the pivotal Phase 3 trial (IOB-013/KN-D18) of lead investigation [Read more]